MedTrace Logo

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

NCT01536886 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 376

Last updated 2025-03-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate whether LEO 90100 and calcipotriol plus betamethasone are effective in the treatment of psoriasis vulgaris.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

LEO 90100

DRUG

Betamethasone plus calcipotriol

DRUG

Ointment vehicle

DRUG

LEO 90100 vehicle

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • John Koo, MD · University of California, San Francisco School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2012-09-30
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01536886 on ClinicalTrials.gov